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It has historically been very difﬁcult to conduct early phase drug studies in children for a number of reasons related to ethics,
acceptability, rarity, standardization, end points, safety, dosing and feasibility. Over the past decade there have been a number of
developments including novel clinical trial design, in silico pharmacology and microdosing that have signiﬁcantly enhanced the
ability of investigators to conduct early phase drug studies in children. While the evolution of drug therapy is creating a series of
new challenges, there has never been a better time for conducting drug studies in children.

Introduction
The current drug development process began after the Elixir
of Sulfanilamide tragedy – in which a number of children
died due to the use of diethylene glycol as a solvent – triggered the passage of the US Food and Drug Act in 1938 [1].
This was intended to ensure that drugs were safe and effective
prior to approval for marketing. It should not be forgotten
that the impetus for this Act was a therapeutic disaster largely
involving children. One consequence of this was the current
drug development process, which after pre-clinical studies
involves Phase I (ﬁrst-in-man), Phase II (ﬁrst-in-patient)
and Phase III (comparison to standard therapy) studies (see
Figure 1). An additional tragedy that spurred changes in drug
regulation was the Thalidomide tragedy in the early 1960s
that led to both the Kefauver-Harris amendments to the Food
and Drug Act in 1962 and the creation of national spontaneous reporting schemes for adverse drug reactions such as the
Yellow Card Scheme in the UK [2, 3]. While children have
beneﬁtted from the spontaneous reporting schemes, the
DOI:10.1111/bcp.13058

other changes that were intended to provide safer drug
therapy for children had quite the opposite effect. The
Kefauver-Harris amendments stated that, in order to be
approved for marketing, a drug must not only be safe but also
have substantial evidence of beneﬁt under the conditions of
use as deﬁned in the product monograph, and provided
powers for the Food and Drug Administration to enforce this.
The result was that, rather than ensuring that well-designed
studies were conducted in children, product monographs
simply stated, in more or less similar terms, that safety and
efﬁcacy of the drug in question had not been evaluated in
children along with a legal disclaimer against use in children
[2]. This unintended consequence of a well-meaning Act was
best described by Shirkey who used the term “the therapeutic
orphan” to describe that the majority of drugs on the market
had no labelling for use in children – despite the fact that
these drugs were commonly used, often as ﬁrst line therapy,
in children [2, 4].
Over the past 20 years there has been a concerted effort to
address these problems, including development of national
© 2016 The British Pharmacological Society
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Figure 1
General overview of the drug development process. Modiﬁed from [6]

and international research networks to conduct drug research
in children as well as changes in the drug approval process by
drug regulatory authorities that have not only increased
knowledge with respect to approved drugs but also have mandated inclusion of children in pre-marketing studies of drugs
likely to be used by children [5]. Examples include the Best
Pharmaceuticals for Children Act and the Pediatric Research
Equity Act that became a permanent part of American law
as part of the Congressional approval of the FDA Safety and
Innovation Act in 2012 and the European equivalent, the
Regulation on Medicines for Paediatric Use [5, 6]. The regulatory agencies on both sides of the Atlantic have the ability –
and indeed the mandate – to require companies making
new drug submissions to provide a detailed plan (Pediatric
Study Plan in the US, Paediatric Investigation Plan in Europe)
for drugs likely to be used in children. New therapies that are
likely to be useful in the treatment of children will therefore
need to include children as part of their drug development
plans [7, 8]. This will create challenges as this has historically
not been part of drug development planning for most new
therapeutic entities, but there are also a number of advances
that present opportunities to address this.
The conduct of early phase drug research is challenging at
the best of times [9]. There are a number of speciﬁc issues germane to enrolment of children in early phase drug trials and
these will be considered in turn.

between a somewhat laissez faire approach to inclusion of
children in drug studies with the arguably nihilistic view that
children should not be involved in drug studies [9–12]. Over
the past decade the argument has increasingly been made
that drug studies in children are essential in order to provide
evidence to guide safe and effective drug therapy and to facilitate the development of drugs for common and important
paediatric disorders [13].
There are now ethical constructs that permit and even encourage involvement of children in drug research, notably
when this will be of material beneﬁt to children with disorders targeted by the agent in question. On-going discourse
has evolved to increasingly include discussion of the idea that
involvement in research would not present more than minimal risk. While avoiding minimal risk usually means that,
with the exception of children with cancer, it is unlikely children will be involved in Phase I studies, but children would
certainly be ethically eligible for Phase II and Phase III studies
(see Table 1). There have been increasing calls that ethical approval would require not only consent from parents but also
assent from the children, certainly for adolescents [14–16].
The question of how best to secure informed consent for drug
research in adolescents remains problematic, in that in many
jurisdictions minors can give informed consent for signiﬁcant medical procedures – including those associated with
signiﬁcant risk – but often cannot themselves give consent
for participation even in very low risk research studies. This
remains an area of active debate and discussion.

Ethics
The involvement of children in research studies has been
hotly debated and this is a ﬁeld in constant ﬂux. Since the
“Great Divide” after World War II that established the importance of research ethics and informed consent, there has been
an on-going debate as to the ethical issues involved in the
participation of children in research [9–11]. This has been
true in the United States, Europe (ftp://ftp.cordis.europa.eu/
pub/fp7/docs/ethical-considerations-paediatrics_en.pdf),
Canada (http://www.pre.ethics.gc.ca/eng/policy-politique/
initiatives/tcps2-eptc2/Default/) and many other jurisdictions [12]. Historically there has been a pendulum swinging

Acceptability
The issue of acceptability concerns questions for the child’s
family and also for clinicians, institutions and investigators.
Historically it has been believed that parents are reluctant to
enrol their children in clinical trials. Recent work has suggested that this may be more perception than reality [17–
19]. A multi-centre study in France demonstrated that the refusal rate for clinical studies in children was related to the perceived burden on the family on the part of the paediatrician
charged with enrolling patients in the study [20]. This
Br J Clin Pharmacol (2016) 82 1308–1314
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Table 1
Phases of pre-clinical drug development in humans and examples in paediatrics

Phase of drug
development

Goal of studies

Examples in paediatric drug development

Phase I

First stages of drug testing in humans, typically
conducted in health adult volunteers

Very rarely done in children with the exception of oncology
drug (chemotherapy) and some drugs in neonatology (surfactant)

Phase II

First stages of drug testing for efﬁcacy and safety,
typically conducted in patients

Uncommon, and represent the ﬁrst step for most drugs in terms
of early phase studies in children. Regulatory advances have increased
these studies for new drugs

Phase III

Effectiveness of the drug and the role in clinical
practice, typically by comparison with
“gold standard” therapy

Done at some times for drugs in children, most frequently for
anti-infectives and increasingly for other drug classes

supports our ﬁnding in an earlier Anglo-Canadian study that
showed that paediatricians with limited training in ethics
were very reluctant to enrol children in clinical trials [21].
The degree of comfort of study personnel in working with
children and families appears to be a key factor in the success
or failure of drug studies in children with respect to enrolment or lack thereof. It is also increasingly evident that children are interested in being involved in studies for altruistic
reasons with respect to the well-being of other children.
In addition to individual investigators, the degree of comfort with drug studies in children varies considerably between
institutions, sometimes with no clear link between experience in child health care and degree of comfort for recruiting
children to drug studies. In this context, the creation of regional and national networks for children’s research has been
a great opportunity in terms of providing standards and resources to enhance the design and conduct of clinical research – including drug research – in children. An early
example was the National Institutes of Health Pediatric Pharmacology Research Network linking research units throughout the United States, while a more recent example germane
to the UK is the Medicines for Children Research Network
created by the National Health Service which brought together expertise in paediatric drug studies across the UK
[22]. In the latter case this has been merged with the Paediatric Specialty Group to create a community of clinical practice
that provides national research expertise in studies involving
children, including drug studies (https://www.crn.nihr.ac.uk/
children/). This creates the opportunity for shared expertise
and more rapid translation of best practices.

Rarity
The issue of rarity speaks to a dichotomous reality in paediatric health care, in that many disorders are rare at any individual institution but are collectively reasonably common. We
demonstrated this in a study of drug utilization in a cohort
of one million Canadian children followed for a year, in
which 70% of drug use was among 20% of children, these
children representing a number of serious and chronic
conditions [23]. We also found that these children were
mostly cared for in 16 academic health science centres across
the country. Hence, while clinical trials of new therapies are
1310
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clearly needed, it is difﬁcult to use a single centre, and sample
size has been a frequently cited problem for drug studies in
children [6].
Thus, in addition to acceptance, the development of
regional, national and international networks has been instrumental in providing mechanisms for timely recruitment
of large numbers of patients using common instruments
and with the evaluation of common outcomes. This has been
most successful in paediatric haematology-oncology and
neonatology, as both ﬁelds have made considerable progress
in assessing therapy and developing evidence-based treatment protocols which have resulted in the survival of very
small pre-term infants and a very high rate of cure for many
childhood cancers [6, 24, 25]. Increasingly other groups – including academic general paediatricians and critical care paediatricians – are developing networks to apply the strength of
synergy to problems within their care and research domains
[26, 27]. The existence and development of these networks
provides a much improved platform to support drug research
in children. Additionally, these networks can support highly
specialized units such as Phase I units for childhood cancer,
facilities that are uncommon but very important [28, 29].

Standardization, end points and safety
One of the key elements in drug research is the clinical trial.
Since the ﬁrst curative clinical trial – conducted in 1946–47
by the MRC Tuberculosis Research Unit to study streptomycin in the management of pulmonary tuberculosis – the
randomized clinical trial has become a gold standard in the
drug development process [6, 30, 31]. For many years a
randomized placebo-controlled double blind clinical trial
was considered essential to the drug development and approval process. This has been a problem in drug studies in
children for several reasons [6]. There have been issues with
ethical approval and conduct as noted above. There has also
been reluctance to use placebos during drug research in
children. As the number of effective therapies has evolved,
this question has become germane to clinical trials involving adults as well.
A key question is selection of a suitable end point, notably as this drives sample size and analysis strategy [6, 32].
These end points may include biomarkers, the validity of
which may not have been established in children.

Early phase drug studies in children

Development of valid and reproducible end points has become a research ﬁeld in and of itself. An issue that complicates clinical trials in children is that many end points
that are commonly used in adult clinical trials have not
been validated in children – or indeed may not be possible
[6]. As an example, the evaluation of the efﬁcacy of analgesic interventions in young children and infants was problematic as many validated instruments for the evaluation
of pain involved self-report, a problem for populations that
are non-verbal or who lack numerical literacy [33]. However,
great progress has been made over the past two decades in
developing and validating end points that are relevant to
and achievable in studies involving children. To return to
the issue noted above, there have been a number of scales
and observation tools developed that provide investigators
with valid tools to study the effect of various interventions
on pain on even the youngest of infants [33, 34].
In addition to progress in the selection of end points
there have been a number of advances in the design of clinical trials for children (Figure 2). Analysis of clinical trials
conducted in children has suggested that many designs
used to date are associated with a signiﬁcant risk of bias, notably with respect to sequence generation and allocation
concealment [35]. Also, the perception of lack of ﬂexibility
has historically been a problem for randomized drug studies
in children [36]. Over the past decade a number of novel
trial designs have been developed to address these issues.
One example is sequential design in which investigators
conduct frequent analysis during subject enrolment to determine if the therapy of interest is superior [37]. A type of
sequential design suggested to be very useful for studies in
children is adaptive design, in which planned interim
analysis is used to inform modiﬁcations in trial design

[38]. This type of trial requires meticulous pre-trial planning
and consideration of issues such as blinded versus nonblinded interim analysis [39]. This can permit a trial to be
stopped early in the case of an intervention that is either
very effective or found to be ineffective, reducing the
number of children needed for the trial. These trial designs
may be unfamiliar to drug regulatory agencies and investigators planning on using them for early phase drugs studies
are encouraged to discuss this with their respective drug
regulatory agency.
An additional issue of key importance in any clinical
trial, and most certainly those involving drugs, is a robust
and on-going safety assessment [40]. The drug approval
process was designed to detect serious and common risks,
and while this is generally the case, it is clear from such
unfortunate events as that associated with the initial
clinical trials of TGN1412 in the UK and fatty acid amide
hydrolase (FAAH) inhibitors in France, that serious, even
fatal, adverse effects still occur [41]. This is of particular
importance in the drug evaluation process for children as
some common and important adverse drug effects are different in both incidence and manifestation in children than in
adults [42, 43]. The increase in interest in drug therapy for
children over the past two decades has been accompanied
by the development of new instruments both clinically
and in vitro that offer considerable promise for more rapid
and focused detection of adverse drug events in children,
notably for novel therapeutic agents [44, 45].
An emerging area in clinical trial design with special relevance to children is the use of simulation and modelling
early in the drug development process [46, 47]. The value
that simulation and modelling brings is the ability to factor
in variables such as ontogeny of key pathways of drug

Figure 2
Considerations in planning the design of an early phase drug trial in children. A key aspect in planning relates to early decisions as to the need for a
ﬂexible design. Modiﬁed from [6]
Br J Clin Pharmacol (2016) 82 1308–1314
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clearance and data derived from adult studies to develop estimates for drug dosing which enables a clearer estimate of
dose while reducing the requirement for additional studies
[47]. Simulation can also be used to provide ﬁrmer estimates
of sample size and to illustrate the point at which increasing
sample size does not signiﬁcantly increase the precision of
data gathered [47]. The increasing sophistication of
pharmacometrics
in
children
also
provides
new
opportunities.

Dosing and feasibility
There are feasibility issues with respect to involvement of
children in early phase drug studies and ﬁrst among them is
dose selection. The issue of dose selection for Phase I trials is
problematic at the best of times and the increasing percentage of biologicals as new therapeutic entities has only increased this problem. A recent review of failed paediatric
drug development trials has suggested that in up to a quarter
of trials that fail to establish efﬁcacy or safety, the selection of
the correct dose was a factor in this failure [48].
The conventional approach to developing dose considerations for children has been to extrapolate from adult
dosing, often using techniques such as allometric scaling.
This may be problematic in that the major issues in ontogeny directly impact on drug clearance, primarily in terms
of a reduction in the capacity of children to clear drugs or
drug metabolites, notably in infancy [49]. While this is
now well understood for drugs used in the ﬁrst year of life,
an under-appreciated issue is that toddlers are notably more
efﬁcient in terms of oxidative metabolism, which may increase the risk for toxicity in drugs that undergo biotransformation to active metabolites [50].
Better appreciation of the role of ontogeny and disease enables an improved rationale for drug dosing in paediatric
studies [51]. A technique with considerable potential is
microdosing, in which a pharmacokinetic study is performed
using a subtherapeutic dose of a 14C labelled drug [52–54].
This can be done as a “Phase 0” study prior to a Phase 1 or
Phase 2 trial. Advances in analytical technology have been
such that concerns about the volume of blood needed for
pharmacokinetic studies – once a major concern in paediatrics – is now largely a historical curiosity except for very premature infants.
Once a dose has been selected, a consideration somewhat
unique to paediatric drug studies is formulation. While drugs
for adults – notably chronic therapy – are overwhelmingly
given orally as tablets or capsules, the use of drugs in children
must take into account the fact that medication naïve children under the age of 8 ﬁnd it difﬁcult to take tablets or capsules and even medication sophisticated children cannot
reliably take medication in conventional tablets or capsules.
The traditional approach to this problem has been to develop
liquid formulations or to crush the tablets [55]. Over the past
decade there has been an explosion in the creation of novel
dosing systems designed for children, work largely driven by
developments in Europe and which offers great promise for
making drug research – and drug therapy – much more practical for infants and small children [56].
1312
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Moving forward
While there have been many cultural, scientiﬁc and regulatory challenges that have made conducting early phase clinical trials in children difﬁcult, developments over the past
decade have addressed many of these issues and have provided the opportunity – indeed, in some cases the requirement – for the inclusion of children even in early stages of
drug development. While there are new issues – such as the
development of drugs for the neonate, the increasing appreciation of the importance of drug transporters in drug disposition in children and the complex issues raised by the
increasing use of biologicals – that pose new and interesting
challenges for paediatric pharmacy and clinical pharmacology – there has never been a more promising time for drug development in children [57–60].
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